
Illumina


Sustainable Growth Hypothesis:

As the global leader in gene sequencing, Illumina occupies a privileged position in the genomics value chain and has clear potential to make a difference by enabling scientific and medical advances.

1. Growth: How likely is the company to deliver 10% p.a. profit growth over the next decade?

- Illumina provides key infrastructure for growth in the genomics market. While growth under the last CEO was disappointing, we believe the new CEO will bring a renewed focus to profitability of the core business.
- 2. Resilience: How much control does the company have over its own success?
- Illumina's large installed base, along with high switching costs for customers, and significant scale versus peers means it boasts a strong competitive position. Furthermore, 85% of revenues are recurring – an indicator that its customer base remains stable and cash flows are reliable.
- 3. Valuation: What is our insight?
- Our willingness to remain patient in the wake of longer duration cash flows, look past short-term fluctuations, and remain close to management through our relationships that strengthen over time.
- 4. Products: To what extent will the core products & services create value for society over the next decade?
- Illumina has handled >90% of genomes ever sequenced. Most cancer tests, and all single-cell sequencing currently rely on its devices. Its success has enabled economies of scale that have driven down the cost of sequencing dramatically over the last 12 years.
- 5. Practices: Does the company show leadership in its business practices?
- Allegations of keeping prices high have remained a priority for engagement. Handling of the recent attempted GRAIL acquisition also raised questions about decision-making and focus, but recent management changes have helped us gain confidence in the future direction of the company.
- 6. Ambition: What is the company's purpose, and how ambitious are they?
- The founding principles were focused on societal benefit. We continue to monitor if this still drives the company's growth.
- 7. Trust: Should we trust the company with our clients' capital?
- We have open lines of communication with management which have proved invaluable in 2023.
 With the new CEO in place, and a trusted Board, there is a chance for Illumina to restore confidence among its stakeholders.
- 8. Engagement: No company is perfect, what should be our engagement priority?
- Our focus will be to remain close to the refreshed management team and strategic decisions they
 make around focusing on returning to growth in the core business.
- 9. Milestones: What developments should we pay most attention to? Where could we be wrong?
- We must stay alert to growing competition in the genomics market and whether Illumina continues to have significant scale and competitive advantages over peers.





Important information and risk factors

All investment strategies have the potential for profit and loss.

Stock Examples

Any stock examples, or images, used in this presentation are not intended to represent recommendations to buy or sell, neither is it implied that they will prove profitable in the future. It is not known whether they will feature in any future portfolio produced by us.

Any individual examples will represent only a small part of the overall portfolio and are inserted purely to help illustrate our investment style.

Important Information

Baillie Gifford & Co (BG & Co), Baillie Gifford & Co Limited (BG & Co Ltd), Baillie Gifford Overseas Limited (BGO) and Mitsubishi UFJ Baillie Gifford Asset Management Limited (MUBGAM) are authorised and regulated by the FCA in the UK. BG & Co Ltd is an Authorised Corporate Director of OEICs.

Baillie Gifford Investment Management (Europe) Limited (BGE), Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 (BGA) and Baillie Gifford International LLC (BGI) are wholly owned by BGO. BGO and BG & Co Ltd are wholly owned by BG & Co.

BGI and BGO are registered with the SEC in the United States of America.

BG & Co claims compliance with the Global Investment Performance Standards (GIPS®). An example of a compliant composite presentation, a complete list of the Firm's composites and performance results is available on request.

BGO provides investment management and advisory services to non-UK Professional/Institutional clients only.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

This presentation contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research and Baillie Gifford and its staff may have dealt in the investments concerned.

BGE provides investment management and advisory services to European (excluding UK) clients. It was incorporated in Ireland in May 2018. Baillie Gifford Investment Management (Europe) Limited is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. Baillie Gifford Investment Management (Europe) Limited is also authorised in accordance with Regulation 7 of the AIFM Regulations, to provide management of portfolios of investments, including Individual Portfolio Management ('IPM') and Non-Core Services. Baillie Gifford Investment Management (Europe) Limited has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc. Through passporting it has established Baillie Gifford Investment

Management (Europe) Limited (Frankfurt Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in Germany. Similarly, it has established Baillie Gifford Investment Management (Europe) Limited (Amsterdam Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in The Netherlands.BGE also has a representative office in Zurich, Switzerland pursuant to Art. 58 of the Federal Act on Financial Institutions ("FinIA"). The representative office is authorised by the Swiss Financial Market Supervisory Authority (FINMA). The representative office does not constitute a branch and therefore does not have authority to commit Baillie Gifford Investment Management (Europe) Limited.

BGA holds a Type 1 and a Type 2 licence from the Securities and Futures Commission of Hong Kong to market and distribute Baillie Gifford's range of collective investment schemes to professional investors in Hong Kong. BGA can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong, Telephone +852 3756 5700.

Important Information Australia

Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This material is provided to you on the basis that you are a "wholesale client" within the meaning of section 761G of the Corporations Act 2001 (Cth) ("Corporations Act"). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this document be made available to a "retail client" within the meaning of section 761G of the Corporations Act. This material contains general information only. It does not take into account any person's objectives, financial situation or needs.

Important Information South Korea

BGO is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.

Important Information North America

BGI was formed in Delaware in 2005. It is the legal entity through which BGO provides client service and marketing functions in North America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. BGO is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission ('OSC'). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. BGI is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. BGE relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.

Important information and risk factors

Important Information South Africa

BGO is licensed with the Financial Sector Conduct Authority in South Africa as a Financial Services Provider (FSP No 44870) in terms of section 8 of the Financial Advisory and Intermediary Services Act, 2002. This licence authorises BGO to carry on financial intermediary services business on behalf of South African clients.

Important Information Israel

BGO is not licensed under Israel's Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755-1995 (the "Advice Law") and does not carry insurance pursuant to the Advice Law. This presentation is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

Important Information Japan

MUBGAM is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and BGO.

Financial Intermediaries

This document is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

BGI Principal Office: Calton Square, 1 Greenside Row, Edinburgh EH1 3AN, Scotland. Telephone: +44 (0)131 275 2000

780 Third Avenue, 43rd Floor, New York, NY 10017. Telephone: (212) 319 4633

BGE Head Office: 4/5 School House Lane East, Dublin 2 D02 N279, Ireland. Telephone: +35 315 294 150

BGE Frankfurt Branch: WINX Tower, Neue Mainzer Str. 6-10, 60311 Frankfurt, Germany

BGE Amsterdam Branch: Atrium Building, Strawinskylaan 3051, 4th Floor, 1077 ZX Amsterdam, The Netherlands

BGE Representative Office: Bahnhofstr. 10 / Börsenstr. 18 CH - 8001 Zürich, Switzerland

bailliegifford.com